Study MAG104615, a Proof of Concept Study for GSK249320 Versus Placebo in Stroke Patients
Latest Information Update: 17 Dec 2023
At a glance
- Drugs Refanezumab (Primary)
- Indications Stroke
- Focus Proof of concept; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 24 Feb 2017 Results presented at the 42nd International Stroke Conference
- 22 Feb 2017 Primary endpoint (Mean change in gait velocity) has not been met, according to the results published in the Stroke.
- 22 Feb 2017 Results published in the Stroke